This job is closed
Applications are no longer available for this announcement. Explore current related opportunities below.
Job description
About Us
Protagonist Therapeutics is a discovery-through-late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
About Us
Protagonist Therapeutics is a discovery-through-late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at
Position Summary
Protagonist Therapeutics, Inc is seeking an experienced professional to join the Clinical Pharmacology and Pharmacometrics department. The candidate will lead and execute clinical pharmacology and pharmacometrics efforts for a portfolio of clinical studies, spanning first-in-human through late-stage development. Working in close partnership with cross-functional partners, the candidate will develop and execute clinical pharmacology plans and serve as a functional representative on development teams and regulatory interactions. The candidate will contribute to and conduct PK/PD and quantitative analyses and interpretation of clinical pharmacology studies.
We are committed to a thriving in-office culture. This role requires being on-site at our office in Newark, CA 4 days a week.
Responsibilities
Lead the development and execution of integrated clinical pharmacology, pharmacometrics and model-informed drug development activities across all stages of development
Provide scientific and strategic leadership and execute population PK, PK/PD, exposure-response, and PBPK modeling to support dose selection, study design, regulatory interactions, and key development decisions
Work in partnership with members of cross-functional teams to lead, develop and execute clinical pharmacology plans
Provide scientific and operational leadership to progress development candidates from discovery through late-stage clinical development
Develop and execute quantitative plans to support clinical development of pipeline projects
Contribute to regulatory submissions
Mentor and develop clinical pharmacology scientists, fostering scientific excellence, collaboration, and professional growth within the department.
Required Skills & Qualifications
Advanced degree (PhD, MD, PharmD) in pharmaceutical or pharmacology-related discipline or quantitative sciences
A minimum of 10 years of industry experience with focus on clinical development or application of quantitative sciences
Significant experience with clinical pharmacology, including PK/PD, quantitative sciences, biomarkers and analyses of clinical trials
Demonstrated experience developing and executing clinical pharmacology programs supporting first-in-human and clinical development programs
Demonstrated ability to manage multiple priorities and be productive and successful working cross-functionally in a fast-paced, matrixed organization
Strong scientific background, demonstrated through peer-reviewed publications, regulatory interactions, and presentations.
Working knowledge of regulatory guidance related to clinical pharmacology and pharmacokinetics
Excellent written and oral communication, including ability to convey complex concepts, with the ability to build strong working relationships with colleagues, cross‑functional teams, and external partners
Attention to detail with a consistent focus on quality
Ability to effectively present information to stakeholders
Pay Range
The base pay range for this position at commencement of employment is expected to be between $275,000 and $310,000/year; however, base pay offered may vary depending on multiple individualized factors, including market location, job‑related knowledge, skills, and experience.
Benefits
A top priority for Protagonist Therapeutics, Inc. is to provide a robust and comprehensive health and wellness program for our employees and their families. We offer a variety of high-quality coverage and benefit options.
Health Care benefits. Protagonist covers 100% of the premium cost for medical, dental, and vision coverage for all full-time employees and their dependents.
Flexible Spending Accounts – Healthcare FSA, Dependent Care FSA, Commuter Benefits
401(k) Plan
Flexible Vacation Policy
Life Insurance (Basic, Voluntary & AD&D)
Short Term & Long Term Disability
Company paid lunch and snacks
#J-18808-Ljbffr
Worksite address
newark, CA, 94560, US
Who can apply
Review the original listing for work authorization, qualifications and employer requirements.